$ISRG

Brosius Mark sold $29K of ISRG

Brosius Mark (EVP & Chief Mfg and Supply Cha) sold 69 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $421.80 ($420.12–$424.14) across 3 trades over 2026-06-08 to 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brosius Mark
Published Jun 10, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The filing provides transparency on officer selling activity but does not introduce new business, regulatory, or financial information.

02

Market read

Useful for monitoring insider behavior, but the disclosed sale size and 10b5-1 structure suggest limited trading edge.

03

What to watch

Traders may over-weight small insider sales; the more relevant signal would be large, non-10b5-1 sales or purchases, which are not present here.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-10 (transactions dated 2026-06-08 to 2026-06-10).

Background

The article is an SEC Form 4 insider transaction filing (open-market sale) for Intuitive Surgical.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Intuitive Surgical Form 4 shows EVP Mark Brosius sold 69 shares in open-market transactions at ~$420.12–$424.14 (10b5-1 plan).

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The disclosure is a small, pre-arranged Rule 10b5-1 sale by an officer, with no accompanying operational/regulatory/financial catalyst in the text.

Market effects

Minimal; this is company-specific insider activity with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Because it’s explicitly a pre-arranged 10b5-1 plan, the sale may be mechanically scheduled and not a bearish read-through.

Key entities

  • Intuitive Surgical

    Company whose insider transaction is disclosed on SEC Form 4.

  • Brosius Mark

    EVP & Chief Mfg and Supply Chain officer who sold shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3